X

Clinical Trials

Contact Us

A031702 (Miscellaneous GU Tract Histologic Variants cohort temp suspended 9/23/19) (Small cell ca of bladder cohort temp suspended 12/19/19) (Adenocarcinoma of the Bladder Cohort Suspended 1/22/20)

Study Number: A031702 (Miscellaneous GU Tract Histologic Variants cohort temp suspended 9/23/19) (Small cell ca of bladder cohort temp suspended 12/19/19) (Adenocarcinoma of the Bladder Cohort Suspended 1/22/20)

This phase II trial studies how well the combination of cabozantinib, nivolumab, and ipilimumab work in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination of cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Contact Person(s)
  • MBMC, Henry Robinson, 314-996-5865

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.